A Randomized, Double-blind, Multi-center Phase III Study of Brivanib plus Best Supportive Care (BSC) versus Placebo plus BSC in Subjects with Advanced Hepatocellular Carcinoma (HCC) who have Failed or are Intolerant to Sorafenib

Authors
Category Primary study
Registry of TrialsBrazilian Registry of Clinical Trials
Year 2011
This article has no abstract
Epistemonikos ID: 763032542cd1caa69798accf47f6306c2975b064
First added on: Apr 16, 2025